KB-1420

AS63997VH5-hIgG1-FC

45666

Home » Antibodies » AS63997VH5-hIgG1-FC

Background of AS63997VH5-hIgG1-FC

Delta-like ligand 3 (DLL3) emerges as an inhibitory ligand within the Notch pathway, noted for its pronounced upregulation and aberrant presentation on the cell surface in small cell lung cancer (SCLC) and other high-grade neuroendocrine tumors. The distinctive expression profile of DLL3, characterized by heightened and homogeneous cell surface expression in tumors, juxtaposed with subdued and cytoplasmic expression in select normal tissues, has paved the way for the development of therapeutics targeting DLL3 to specifically address SCLC cells. These DLL3-specific agents are presently under evaluation in numerous ongoing clinical investigations focused on SCLC and other neuroendocrine tumors.

Specifications

Catalog Number	KB-1420
Antibody Name	AS63997VH5-hIgG1-FC
Isotype	Human IgG1
Target	DLL3
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Chapman G, Sparrow DB, Kremmer E, Dunwoodie SL (March 2011). "Notch inhibition by the ligand Delta-Like 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis". Human Molecular Genetics. 20 (5): 438–41.